Scholarlink

Purpose of Review <p>The purpose of this review is to evaluate how effective pharmacogenomic (PGx)-based care is in the treatment of depression. The clinical outcomes are also compared, such as response and remission rates with the current standards of care.</p> Recent Findings <p>Multiple studies critically analyzed in this study showed mixed findings regarding the effectiveness of PGx-based care compared to current standard management. Symptomatic improvement is similar between the two strategies in the early stage of treatment, resulting in better response and remission rates, especially among patients treated with conventional-based therapy. PGx-based care, however, is noted to be more cost-effective for intractable cases of depression. The heterogeneity in the studies analyzed is minimal, making for consistent and general findings.</p> Summary <p>PGx-guided care shows a promising alternative in improving the response and remission rates among patients with depression, especially among those with genetic variants that affect drug metabolism. Although it may not outperform the current standard of care in symptomatic relief in the early stage, its potential cannot be ignored. Reducing side effects and allowing for better selection strategies in treatment-resistant cases are added benefits. There is a need for long-term studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluating The Effectiveness of Pharmacogenomics-Based Care in Depression Compared to Standard Care: A Review of Current Evidence

  • 期刊论文

  • 发表日期：

    2025年3月6日

查看全文
  • Chinonyelum Emmanuel Agbo,
  • Ikponmwosa Jude Ogieuhi,
  • Chidera Stanley Anthony,
  • Victor Oluwatomiwa Ajekiigbe,
  • Abdulrahmon Moradeyo,
  • Adetola Emmanuel Babalola,
  • Victory Aghogho Emojevwe

摘要

Purpose of Review

The purpose of this review is to evaluate how effective pharmacogenomic (PGx)-based care is in the treatment of depression. The clinical outcomes are also compared, such as response and remission rates with the current standards of care.

Recent Findings

Multiple studies critically analyzed in this study showed mixed findings regarding the effectiveness of PGx-based care compared to current standard management. Symptomatic improvement is similar between the two strategies in the early stage of treatment, resulting in better response and remission rates, especially among patients treated with conventional-based therapy. PGx-based care, however, is noted to be more cost-effective for intractable cases of depression. The heterogeneity in the studies analyzed is minimal, making for consistent and general findings.

Summary

PGx-guided care shows a promising alternative in improving the response and remission rates among patients with depression, especially among those with genetic variants that affect drug metabolism. Although it may not outperform the current standard of care in symptomatic relief in the early stage, its potential cannot be ignored. Reducing side effects and allowing for better selection strategies in treatment-resistant cases are added benefits. There is a need for long-term studies.